{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:16:51Z","timestamp":1794835011470,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03613-6","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:54:57Z","timestamp":1776142497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)"],"prefix":"10.1186","volume":"27","author":[{"given":"Tania","family":"Hugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Leander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Palm\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erol","family":"Wiegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Close","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G","family":"Belvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"3613_CR1","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","volume":"50","author":"BN Lambrecht","year":"2019","unstructured":"Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50:975\u201391.","journal-title":"Immunity"},{"key":"3613_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0140-6736(19)33005-3","volume":"395","author":"MC Peters","year":"2020","unstructured":"Peters MC, Wenzel SE. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet. 2020;395:371\u201383.","journal-title":"Lancet"},{"key":"3613_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/JAA.S52387","volume":"7","author":"A Vatrella","year":"2014","unstructured":"Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014;7:123\u201330.","journal-title":"J Asthma Allergy"},{"key":"3613_CR4","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455\u201366.","journal-title":"N Engl J Med"},{"key":"3613_CR5","doi-asserted-by":"crossref","unstructured":"Liang W, Pan HW, Vllasaliu D, Lam JKW. Pulmonary delivery of biological drugs. Pharmaceutics. 2020;12:1025.","DOI":"10.3390\/pharmaceutics12111025"},{"key":"3613_CR6","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1007\/s12325-023-02671-2","volume":"40","author":"A Antalfy","year":"2023","unstructured":"Antalfy A, Berman K, Everitt C, Alten R, Latymer M, Godfrey CM. The adherence and outcomes benefits of using a connected, reusable auto-injector for self-injecting biologics: a narrative review. Adv Ther. 2023;40:4758\u201376.","journal-title":"Adv Ther"},{"key":"3613_CR7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","volume":"7","author":"A St Clair-Jones","year":"2020","unstructured":"St Clair-Jones A, Prignano F, Goncalves J, Paul M, Sewerin P. Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. 2020;7:741\u201357.","journal-title":"Rheumatol Ther"},{"key":"3613_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40259-018-0278-1","volume":"32","author":"C Rothe","year":"2018","unstructured":"Rothe C, Skerra A. Anticalin\u00ae proteins as therapeutic agents in human diseases. BioDrugs. 2018;32:233\u201343.","journal-title":"BioDrugs"},{"key":"3613_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.xphs.2020.09.006","volume":"110","author":"T Sou","year":"2021","unstructured":"Sou T, Bergstrom CAS. Contemporary formulation development for inhaled pharmaceuticals. J Pharm Sci. 2021;110:66\u201386.","journal-title":"J Pharm Sci"},{"key":"3613_CR10","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1007\/s13346-025-01909-6","volume":"15","author":"NA Shaibie","year":"2025","unstructured":"Shaibie NA, Mohammad Faizal NDF, Buang F, Srichana T, Mohd Amin MCI. Inhaled biologics for respiratory diseases: clinical potential and emerging technologies. Drug Deliv Transl Res. 2025;15:4098\u2013114.","journal-title":"Drug Deliv Transl Res"},{"key":"3613_CR11","doi-asserted-by":"crossref","unstructured":"Asimus S, Sadiq M, Cooper J, Dosanjh D, Zhou X-H, Pandya H, et al. Pharmacokinetics of AZD8630\/AMG 104 inhaled anti-TSLP in healthy adults and asthma patients. Eur Respir J. 2024;64(suppl 68):PA3558.","DOI":"10.1183\/13993003.congress-2024.PA3558"},{"key":"3613_CR12","doi-asserted-by":"crossref","unstructured":"Doffman S, Dosanjh D, Sadiq MW, Asimus S, Cooper J, Zhou X-H, et al. Phase 1 safety and efficacy of AZD8630\/AMG 104 inhaled anti-TSLP in healthy volunteers and patients with asthma on medium-high dose inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) with elevated baseline fractional exhaled nitric oxide (FeNO). Am J Respir Crit Care Med. 2024;209:A1386.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1386"},{"key":"3613_CR13","doi-asserted-by":"crossref","unstructured":"Gauvreau GM, Hohlfeld JM, FitzGerald JM, Boulet LP, Cockcroft DW, Davis BE, et al. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. Eur Respir J. 2023;61:2201193.","DOI":"10.1183\/13993003.01193-2022"},{"key":"3613_CR14","doi-asserted-by":"crossref","unstructured":"Scott IC, Kovacina K, Cardner M, Ghandi AV, Tran J, Terrillon S, et al. Proof of mechanism for an inhaled anti-TSLP fragment antibody, AZD8630\/AMG104, in a phase 1 study in healthy adults and asthma patients. Eur Respir J. 2024;64(suppl 68):OA3652.","DOI":"10.1183\/13993003.congress-2024.OA3652"},{"key":"3613_CR15","doi-asserted-by":"crossref","unstructured":"Matschiner G, Allersdorfer A, Rattenstetter B, Gille H, Hohlbaum A, Taylor J, et al. Discovery and development of AZD1402\/PRS-060 a potent and selective blocker of the IL-4 receptor alpha. Am J Respir Crit Care Med. 2018;197:A1354.","DOI":"10.1183\/13993003.congress-2018.PA1047"},{"key":"3613_CR16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.jaci.2022.12.815","volume":"151","author":"G Matschiner","year":"2023","unstructured":"Matschiner G, Fitzgerald MF, Moebius U, Hohlbaum AM, Gille H, Jensen K, et al. Elarekibep (PRS-060\/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma. J Allergy Clin Immunol. 2023;151:966\u201375.","journal-title":"J Allergy Clin Immunol"},{"key":"3613_CR17","doi-asserted-by":"crossref","unstructured":"Pardali K, Jiang F, Fitzgerald M, Matschiner G, Keeling D. AZD1402\/PRS-060, an inhaled Anticalin\u00ae IL-4Ra antagonist, potently inhibits IL-4 induced functional effects in human whole blood, which can be employed translationally in clinical studies. Eur Respir J. 2018;52(suppl 62):PA5248.","DOI":"10.1183\/13993003.congress-2018.PA5248"},{"key":"3613_CR18","doi-asserted-by":"crossref","unstructured":"Bruns I, Fitzgerald M, Mensing G, Tsung M, Pardali K, Gardiner P, et al. Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402\/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma. Eur Respir J. 2019;54(suppl 63):PA3709.","DOI":"10.1183\/13993003.congress-2019.PA3709"},{"key":"3613_CR19","unstructured":"Bruns I, Lickliter J, Aviano K, Fitzgerald MF, Mensing G, Tsung MJ, et al. Elarekibep, an inhaled anticalin protein, targets IL-4R\u03b1 locally: first-in-human randomized phase 1 trials of a novel potential therapeutic class in asthma. In press. 2025."},{"key":"3613_CR20","doi-asserted-by":"crossref","unstructured":"Hugo T, Harper AR, Leander J, Lundin P, Bock D, Zhou X-H, et al. APATURA: a phase 2a study of elarekibep, an inhaled IL-4 receptor alpha inhibitor, in moderate-to-severe asthma. Eur Respir J. 2024;64(suppl 68):PA2980.","DOI":"10.1183\/13993003.congress-2024.PA2980"},{"key":"3613_CR21","unstructured":"Clinical.Trials.gov. Efficacy and safety of inhaled AZD1402 administered for four weeks in adults with asthma on medium-to-high dose inhaled corticosteroids (APATURA). 2023. [https:\/\/clinicaltrials.gov\/study\/NCT04643158?cond=NCT04643158&rank=1]. Accessed 30 June 2025."},{"key":"3613_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/0192623320976094","volume":"49","author":"AP Hall","year":"2021","unstructured":"Hall AP, Tepper JS, Boyle MH, Cary MG, Flandre TG, Piaia A, et al. BSTP review of 12 case studies discussing the challenges, pathology, immunogenicity, and mechanisms of inhaled biologics. Toxicol Pathol. 2021;49:235\u201360.","journal-title":"Toxicol Pathol"},{"key":"3613_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0192623321988841","volume":"49","author":"A Wolfreys","year":"2021","unstructured":"Wolfreys A, Kilgour J, Allen AD, Dudal S, Freke M, Jones D, et al. Review of the technical, toxicological, and PKPD considerations for conducting inhalation toxicity studies on biologic pharmaceuticals-the outcome of a cross-industry working group survey. Toxicol Pathol. 2021;49:261\u201385.","journal-title":"Toxicol Pathol"},{"key":"3613_CR24","doi-asserted-by":"publisher","first-page":"e0207767","DOI":"10.1371\/journal.pone.0207767","volume":"13","author":"O Danov","year":"2018","unstructured":"Danov O, Jimenez Delgado SM, Obernolte H, Seehase S, Dehmel S, Braubach P, et al. Human lung tissue provides highly relevant data about efficacy of new anti-asthmatic drugs. PLoS One. 2018;13:e0207767.","journal-title":"PLoS ONE"},{"key":"3613_CR25","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaci.2012.03.030","volume":"130","author":"RE Slager","year":"2012","unstructured":"Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol. 2012;130:516\u201322. e514.","journal-title":"J Allergy Clin Immunol"},{"key":"3613_CR26","doi-asserted-by":"crossref","unstructured":"Bruns I, Fitzgerald M, Pardali K, Gardiner P, Keeling D, Axelsson L, et al. First-in-human data for the inhaled IL-4Ra antagonist, AZD1402\/PRS-060, reveals a promising clinical profile for the treatment of asthma. Am J Respir Crit Care Med. 2019;199:A7476.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A7476"},{"key":"3613_CR27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1177\/0091270009341183","volume":"49","author":"E Burmeister Getz","year":"2009","unstructured":"Burmeister Getz E, Fisher DM, Fuller R. Human pharmacokinetics\/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol. 2009;49:1025\u201336.","journal-title":"J Clin Pharmacol"},{"key":"3613_CR28","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396.","journal-title":"N Engl J Med"},{"key":"3613_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","volume":"62","author":"A Kychygina","year":"2022","unstructured":"Kychygina A, Cassagne M, Tauber M, Galiacy S, Paul C, Fourni\u00e9 P, et al. Dupilumab-associated adverse events during treatment of allergic diseases. Clin Rev Allergy Immunol. 2022;62:519\u201333.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3613_CR30","unstructured":"GINA. Difficult-to-treat and severe asthma in adolescents and adult patients. Diagnosis and management. 2023. [https:\/\/ginasthma.org\/wp-content\/uploads\/2023\/09\/GINA-Severe-Asthma-Guide-2023-WEB-WMS.pdf]. Accessed 1 July 2025."},{"key":"3613_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.addr.2014.05.017","volume":"75","author":"C Loira-Pastoriza","year":"2014","unstructured":"Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev. 2014;75:81\u201391.","journal-title":"Adv Drug Deliv Rev"},{"key":"3613_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12325-015-0201-9","volume":"32","author":"N Scichilone","year":"2015","unstructured":"Scichilone N. Asthma control: the right inhaler for the right patient. Adv Ther. 2015;32:285\u201392.","journal-title":"Adv Ther"},{"key":"3613_CR33","first-page":"2732017","volume":"2018","author":"JM Borghardt","year":"2018","unstructured":"Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018;2018:2732017.","journal-title":"Can Respir J"},{"key":"3613_CR34","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1080\/17425247.2021.1886074","volume":"18","author":"AD Brunaugh","year":"2021","unstructured":"Brunaugh AD, Sharma S, Smyth H. Inhaled fixed-dose combination powders for the treatment of respiratory infections. Expert Opin Drug Deliv. 2021;18:1101\u201315.","journal-title":"Expert Opin Drug Deliv"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03613-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:40:57Z","timestamp":1781224857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03613-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3613"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03613-6","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Council for Harmonisation (ICH)\/Good clinical practice (GCP) guidelines, applicable regulatory requirements and the AstraZeneca policy on Bioethics. All patients provided written informed consent. The study protocol, the participant information and consent form, and other relevant study documentation were approved by the independent ethics committee\/institutional review boards from each participating country (Supplemental Table S6).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Tania Hugo, Andrew R Harper, Jacob Leander, P\u00e5l Lundin, David Bock, Xiao-Hong Zhou, David R Close and Hitesh Pandya are employees of AstraZeneca and may own stock or stock options. Steve Burns, Philip Gardiner, Robert Palm\u00e9r, David J Keeling and Maria G Belvisi are former employees of AstraZeneca and may own stock or stock options. Irina Bondarenko is an employee of Parexel Int. Erol Wiegert and Mary F Fitzgerald were consultants for Pieris Pharmaceuticals at the time study was conducted and may own stock or stock options. Paul M O\u2019Byrne has received grants and consultancy fees from AstraZeneca, GSK, MedImmune and Novartis; consultancy fees from Covis Pharma and Teva Pharmaceuticals; speaker fees from AstraZeneca, Chiesi and Menarini Group; and grants from Bayer and Merck.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}